Literature DB >> 28639341

Rigidity of the extracellular part of HER2: Evidence from engineering subdomain interfaces and shared-helix DARPin-DARPin fusions.

Christian Jost1, Jakob C Stüber1, Annemarie Honegger1, Yufan Wu1, Alexander Batyuk1, Andreas Plückthun1.   

Abstract

The second member of the human ErbB family of receptor tyrosine kinases, HER2/hErbB2, is regarded as an exceptional case: The four extracellular subdomains could so far only be found in one fixed overall conformation, designated "open" and resembling the ligand-bound form of the other ErbB receptors. It thus appears to be different from the extracellular domains of the other family members that show inter-subdomain flexibility and exist in a "tethered" form in the absence of ligand. For HER2, there was so far no direct evidence for such a tethered conformation on the cell surface. Nonetheless, alternative conformations of HER2 in vivo could so far not be excluded. We now demonstrate the rigidity of HER2 on the surface of tumor cells by employing two orthogonal approaches of protein engineering: To directly test the potential of the extracellular domain of HER2 to adopt a pseudo-tethered conformation on the cell surface, we first designed HER2 variants with a destabilized interface between extracellular subdomains I and III that would favor deviation from the "open" conformation. Secondly, we used differently shaped versions of a Designed Ankyrin Repeat Protein (DARPin) fusion, recognizing subdomain I of HER2, devised to work as probes for a putative pseudo-tethered extracellular domain of HER2. Combining our approaches, we exclude, on live cells and in vitro, that significant proportions of HER2 deviate from the "open" conformation.
© 2017 The Protein Society.

Entities:  

Keywords:  DARPins; ErbB receptors; HER2; conformational probe; protein engineering

Mesh:

Substances:

Year:  2017        PMID: 28639341      PMCID: PMC5563139          DOI: 10.1002/pro.3216

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  32 in total

1.  CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor.

Authors:  Francesca Walker; Suzanne G Orchard; Robert N Jorissen; Nathan E Hall; Hui-Hua Zhang; Peter A Hoyne; Timothy E Adams; Terrance G Johns; Colin Ward; Thomas P J Garrett; Hong-Jian Zhu; Maureen Nerrie; Andrew M Scott; Edouard C Nice; Antony W Burgess
Journal:  J Biol Chem       Date:  2004-03-11       Impact factor: 5.157

2.  Protein complex expression by using multigene baculoviral vectors.

Authors:  Daniel J Fitzgerald; Philipp Berger; Christiane Schaffitzel; Kazuhiro Yamada; Timothy J Richmond; Imre Berger
Journal:  Nat Methods       Date:  2006-12       Impact factor: 28.547

3.  The ErbB4 extracellular region retains a tethered-like conformation in the absence of the tether.

Authors:  Ping Liu; Samuel Bouyain; Charles Eigenbrot; Daniel J Leahy
Journal:  Protein Sci       Date:  2011-11-14       Impact factor: 6.725

4.  The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.

Authors:  Samuel Bouyain; Patti A Longo; Shiqing Li; Kathryn M Ferguson; Daniel J Leahy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

Review 5.  Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs.

Authors:  Christian Jost; Andreas Plückthun
Journal:  Curr Opin Struct Biol       Date:  2014-07-15       Impact factor: 6.809

6.  Structural basis for high-affinity HER2 receptor binding by an engineered protein.

Authors:  Charles Eigenbrot; Mark Ultsch; Anatoly Dubnovitsky; Lars Abrahmsén; Torleif Härd
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-09       Impact factor: 11.205

7.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.

Authors:  Hyun-Soo Cho; Karen Mason; Kasra X Ramyar; Ann Marie Stanley; Sandra B Gabelli; Dan W Denney; Daniel J Leahy
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

8.  Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2.

Authors:  Christian Jost; Johannes Schilling; Rastislav Tamaskovic; Martin Schwill; Annemarie Honegger; Andreas Plückthun
Journal:  Structure       Date:  2013-10-03       Impact factor: 5.006

Review 9.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Authors:  José Baselga; Sandra M Swain
Journal:  Nat Rev Cancer       Date:  2009-06-18       Impact factor: 60.716

Review 10.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

Authors:  Antony W Burgess; Hyun-Soo Cho; Charles Eigenbrot; Kathryn M Ferguson; Thomas P J Garrett; Daniel J Leahy; Mark A Lemmon; Mark X Sliwkowski; Colin W Ward; Shigeyuki Yokoyama
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

View more
  4 in total

1.  Rigid fusions of designed helical repeat binding proteins efficiently protect a binding surface from crystal contacts.

Authors:  Patrick Ernst; Annemarie Honegger; Floor van der Valk; Christina Ewald; Peer R E Mittl; Andreas Plückthun
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

2.  Apoptosis-inducing anti-HER2 agents operate through oligomerization-induced receptor immobilization.

Authors:  Jakob C Stüber; Christian P Richter; Junel Sotolongo Bellón; Martin Schwill; Iwo König; Benjamin Schuler; Jacob Piehler; Andreas Plückthun
Journal:  Commun Biol       Date:  2021-06-21

3.  Rigidly connected multispecific artificial binders with adjustable geometries.

Authors:  Yufan Wu; Alexander Batyuk; Annemarie Honegger; Fabian Brandl; Peer R E Mittl; Andreas Plückthun
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

4.  Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action.

Authors:  Florian Kast; Martin Schwill; Jakob C Stüber; Svende Pfundstein; Gabriela Nagy-Davidescu; Josep M Monné Rodríguez; Frauke Seehusen; Christian P Richter; Annemarie Honegger; Karen Patricia Hartmann; Thomas G Weber; Felix Kroener; Patrick Ernst; Jacob Piehler; Andreas Plückthun
Journal:  Nat Commun       Date:  2021-06-18       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.